During previous cycles of this competing renewal we established the importance of autocrine ErbB family kinase stimulation in colon cancer cell lines. We also developed a sophisticated model in which we have translated these results into xenograft and orthotopic implantation systems. Moreover, we have confirmed that colon cancer metastases from patients reflect the ErbB phenomena we have seen in models. ? A key observation has been that maintenance of the malignant phenotype of colon cancer cells is not dependent upon the amplitude of ErbB signaling. Instead it is the constitutive nature of ErbB family activation that persists in the absence of exogenous ligands that is linked to the malignant phenotype. Characterization of this endogenous activation has allowed us to identify ErbB receptor docking sites that are dependent upon autocrine mechanisms in growth arrest. The hypothesis that these constitutively activated sites are responsible for survival and malignant behavior of colon cancer cells will be tested in Specific Aim I. ? Other studies showed that ErbB2 cooperates with the EGFR in promoting malignancy of colon cancer cells. Specifically, the Y1248 docking site of ErbB2 was found to be autoactivated upon heterodimerization with EGFR. This site specifies signaling modules which are not reiterated by heterodimerized EGFR. The hypothesis that endogenous activation of ErbB2 Y1248 plays a key role in survival and malignant behavior of colon cancer cells will be tested in Specific Aim II. Activation of signal transduction pathways from ErbB family docking sites requires the binding of their specific adaptor molecules. The hypothesis that the specific subset of adaptors binding to endogenously activated docking sites is critical to the survival and malignant behavior of colon cancer cells will be tested in Specific Aim III.
The Specific Aims of this project are: I) Determine whether endogenously activated EGFR docking sites are critical for maintaining the malignant phenotype of colon cancer. II) Determine whether activation of ErbB2 Y1248 is critical to the maintenance of malignancy in colon carcinoma. Ill) Determine whether a specific subset of adaptor proteins linked to endogenously activated ErbB docking sites is critical to maintenance of malignancy in colon cancer. ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Jhappan, Chamelli
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Leiphrakpam, Premila D; Brattain, Michael G; Black, Jennifer D et al. (2018) TGF? and IGF1R signaling activates protein kinase A through differential regulation of ezrin phosphorylation in colon cancer cells. J Biol Chem 293:8242-8254
Contreras, Jacob I; Robb, Caroline M; King, Hannah M et al. (2018) Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. ACS Chem Biol 13:1148-1152
Robb, Caroline M; Kour, Smit; Contreras, Jacob I et al. (2018) Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget 9:5216-5232
Bailey, Katie L; Agarwal, Ekta; Chowdhury, Sanjib et al. (2017) TGF?/Smad3 regulates proliferation and apoptosis through IRS-1 inhibition in colon cancer cells. PLoS One 12:e0176096
Robb, Caroline M; Contreras, Jacob I; Kour, Smit et al. (2017) Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem Commun (Camb) 53:7577-7580
Agarwal, E; Robb, C M; Smith, L M et al. (2017) Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis. Oncogene 36:3104-3118
Fisher, Kurt W; Das, Binita; Kim, Hyun Seok et al. (2015) AMPK Promotes Aberrant PGC1? Expression To Support Human Colon Tumor Cell Survival. Mol Cell Biol 35:3866-79
Leiphrakpam, Premila D; Agarwal, Ekta; Mathiesen, Michelle et al. (2014) In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer. Oncol Rep 31:87-94
Leiphrakpam, Premila D; Rajput, Ashwani; Mathiesen, Michelle et al. (2014) Ezrin expression and cell survival regulation in colorectal cancer. Cell Signal 26:868-79
Agarwal, Ekta; Chaudhuri, Anathbandhu; Leiphrakpam, Premila D et al. (2014) Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer 14:145

Showing the most recent 10 out of 49 publications